

CURRICULUM VITAE

Christopher L. Amling, M.D., F.A.C.S

Oregon Health & Science University
Center for Health & Healing, CH10U
Division of Urology
3303 SW Bond Avenue
Portland, OR 97239

Telephone/Fax: (503) 346-1500/(503)346-1501

Email Address: amling@ohsu.edu

CURRENT POSITION

Professor and Chief, Division of Urology 3/2009 - present
Oregon Health & Science University, Portland, Oregon

PREVIOUS POSITIONS

Professor and Director, Division of Urology 10/2005 – 2/2009
University of Alabama at Birmingham

Endowed Chair:
Anton J. Bueschen Endowed Chair in Urologic Surgery 6/2006 – 2/2009
and Research, Division of Urology, University of
Alabama at Birmingham

Chairman, Department of Urology 2/2004 – 7/2005
Naval Medical Center, San Diego, California

Residency Program Director, Department of Urology 7/2002 – 7/2005
Naval Medical Center, San Diego, California

ACADEMIC APPOINTMENTS

Professor, Department of Surgery, Division of Urology 3/2009 – present
Oregon Health & Science University, Portland, Oregon

Professor, Department of Surgery, Division of Urology 10/2005 – 2/2009
University of Alabama at Birmingham

Senior Scientist, Comprehensive Cancer Center 10/2005 – 2/2009
University of Alabama at Birmingham

EDUCATION

- Undergraduate:** University of Oregon, Eugene, OR 1977-1981
Bachelor of Science, General Science
- Medical School:** Oregon Health Sciences University, Portland, OR 1981-1985
Doctor of Medicine (Cum Laude)
- Internship:** Oakland Naval Hospital, Oakland, CA 1985-1986
General Surgery internship
- Aerospace Medicine:** Naval Flight Surgery Training Program
Naval Aerospace Medical Institute (NAMI)
Pensacola, FL 1987
- Residency:** Duke University Medical Center, Durham, NC 1990-1992
Junior Resident, Department of Surgery
Chairman: David C. Sabiston, M.D.
- Duke University Medical Center, Durham, NC 1992-1996
Resident, Department of Surgery, Division of Urology
Chairman: David F. Paulson, M.D.
- Fellowship:** Mayo Clinic, Rochester, MN 1996-1997
Department of Urology
Urologic Oncology
Fellowship Director: Horst Zincke, M.D., PhD.

MILITARY

- 1981 Full scholarship - Navy Health Professions Scholarship Program
- 1985 Promoted to Lieutenant, U.S. Navy Medical Corps
- 1985 General Surgery Internship, Oakland Naval Hospital
- 1986 Staff Physician, Oakland Naval Hospital Emergency Room
- 1987 Winged U.S. Naval Flight Surgeon, Aerospace Medicine training, Naval Aerospace Medical Institute, Pensacola, FL (Ranked third in class)
- 1987 Flight Surgeon, Marine Air Group-24, Kaneohe Bay, HI
- 1987 Senior Medical Officer and Flight Surgeon, U.S. Marine Corps Medium, Helicopter Squadron-165, Deployment to Okinawa, Japan. Awarded Naval Service and Fleet Marine Force Ribbons
- 1988 Flight Surgeon, VMFA-235 (U.S. Marine Corps fighter/attack squadron), Kaneohe Bay, HI
- 1989 Promoted to Lieutenant Commander, U.S. Navy Medical Corps
- 1997 Staff Urologic Oncologist, Department of Urology, Naval Medical Center, San Diego, CA
- 1997 Promoted to Commander, U.S. Navy Medical Corps
- 1998 Head, Department of Urology, USNS Mercy Hospital Ship, San Diego, CA

- 2003 Promoted to Captain, U.S Navy Medical Corps
2005 U.S Navy Retirement

HONORS AND AWARDS

- 1985 Cum Laude Graduate, Oregon Health Sciences University, School of Medicine
1992 Teaching Resident, Department of Surgery, Duke University Medical Center
1993 Urologic Oncology Award, Division of Urology, Duke University Medical Center
1998 Uro-Oncology Award - Best paper presented at the 46th Annual James C. Kimbrough Urologic Seminar, Williamsburg, VA
1998 Co-Author, Best Resident Paper Award (Second Place), Kimbrough Urologic Seminar, San Antonio, TX
1999 Pfizer Scholar in Urology Award, Department of Urology, Naval Medical Center, San Diego, CA
1999 Senior Author, Best Poster of Session, Western Section AUA Meeting, Palm Desert, CA
2000 Senior Author, Best Paper, Round Table Program, Western Section AUA Meeting, Palm Desert, CA
2000 Navy and Marine Corps Commendation Medal – Meritorious service as a Urologic Oncologist, Department of Urology, Naval Medical Center, San Diego, CA
2001 Senior Author, Best Resident Paper Award (First Place), Kimbrough Urologic Seminar, San Diego, CA
2001 Co-Author, Best Subspecialty Paper, San Diego Section of the American College of Surgeons
2002 Uro-Oncology Award – Best paper presented at the 49th Annual James C. Kimbrough Urologic Seminar, Seattle, WA
2002 Navy and Marine Corps Commendation Medal – Clinical research activity, Clinical Investigation Department, Naval Medical Center, San Diego, CA
2002 Staff Teaching Award, Department of Urology, Naval Medical Center, San Diego, CA
2002 Senior Author, Best Poster of Session (First Place), Western Section AUA Meeting, Kauai, HI
2003 Senior Author, Best Poster of Session (Third place), Western Section AUA Meeting, Las Vegas, NV
2003 Co-Author, First Prize, Miley B. Wesson Resident Essay Competition, Western Section AUA Meeting, Las Vegas, NV
2003 Co-Author, Outstanding Poster Presentation, Society of Urologic Oncology Annual Meeting, Bethesda, MD
2004 Senior Author, First Prize, Resident Academic Competition, San Diego Urologic Society, San Diego, CA
2004 First Prize, Best Staff Research Paper, Academic Research Competition, Clinical Investigation Department, Naval Medical Center, San Diego
2005 Senior Author, Best Resident Paper Award (Third Place), Kimbrough Urologic Seminar, Honolulu, HI
2005 Meritorious Service Medal – Navy career end award for contributions as clinician, researcher, mentor and teacher, Department of Urology, Naval Medical Center, San Diego, CA
2007 Co-Author, First Prize, Montague Boyd Essay Contest, Southeastern Section AUA Meeting, Orlando, FL

LICENSURE AND CERTIFICATION

Diplomate, American Board of Urology, March 1999
Medical License, State of California, License Number G58152 (inactive)

Medical License, State of Minnesota, License Number 38949 (inactive)
Medical License, State of North Carolina, License Number 94-00011 (inactive)
Medical License, State of Hawaii, License Number 6061(inactive)
Medical License, State of Alabama, License Number 26881
Medical License, State of Oregon, License Number MD29001
Diplomate of the National Board of Medical Examiners
Advanced Trauma Life Support (ATLS) Certification
Basic and Advanced Cardiac Life Support (ACLS) Certification

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

Current:

Fellow, American College of Surgeons
American Urologic Association
Southeastern Section of the American Urologic Association (SESAUA)
Local Arrangement Chairman, Southeastern Section AUA Meeting, San Diego, CA (3/08)
Society of Urologic Oncology
Society of University Urologists (SUU)
Executive Board, Society of University Urologists (SUU)
Society of Urology Chairman and Program Directors (SUCPD)
Society of Government Service Urologists (SGSU)

Past:

Western Section, American Urologic Association (1998-2005)
Alternate District Representative, Executive Board, Western Section AUA (2000-2002)
District Representative, Executive Board, Western Section AUA (2003-2005)
Local Arrangements Chairman, Western Section AUA Meeting, San Diego, CA, 8/2004
Vice-President, Uniformed Services Urology Research Group (2002-2003)
President, Uniformed Services Urology Research Group (2004-2005)
Secretary, San Diego Urologic Society (2001-2003)
Vice President, San Diego Urologic Society (2003-2004)
President, San Diego Urologic Society (2005)

NATIONAL COMMITTEES

Residency Review Committee (RRC) for Urology (6/2007 – present)
Program Committee, American Urological Association (5/2006 – present)
Public Media Committee, American Urological Association (5/2006 – present)
American Urologic Association Research Council (5/2004 - present)
Chairman, Fellowship Committee, Society of Urologic Oncology (5/2007 – present)
Secretary, Society of University Urologists (5/2006 – 5/2008)
President-Elect, Society of University Urologists (5/2008 – present)

National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines Panel, Early Detection (10/2007 – present)
ACGME Advisory Committee on Education Outcome Assessment (6/2007 – present)
Prostate Subcommittee, PLCO Screening Trial (7/2007 – present)

SCIENTIFIC ACTIVITIES

Editorial Boards:

Journal of Urology
Prostate Cancer and Prostatic Diseases
Section Editor – Current Prostate Reports

Journal Reviewer:

Journal of Urology
Urology
Prostate Cancer and Prostatic Diseases
European Urology
Journal of the American Medical Association (JAMA)
American Journal of Surgery
Cancer

VISITING PROFESSORSHIPS

- Mayo Clinic, Rochester, MN – January 10-11, 2002
- Walter Reed Army Medical Center, Washington, DC – March 21, 2002
- National Naval Medical Center, Bethesda, MD – March 22, 2002
- Tripler Army Medical Center, Honolulu, HI – August 18-19, 2003
- Mayo Clinic, Scottsdale, AZ – June 7-8, 2004
- University of Minnesota, Minneapolis, MN – September 22-23, 2004
- University of Kansas, Kansas City, KS – April 5-6, 2007

INVITED NATIONAL AND REGIONAL LECTURES

- “Treatment of Advanced Prostate Cancer – A United States Perspective” – Prostate Cancer Global Opinion Leaders Workshop, Paris, France - January 29, 2004
- “Update on Urologic Imaging” and “Update on Prostate Cancer Screening and Biopsy Techniques” – Loma Linda University and USC “Controversies in Urology” Meeting, Mammoth, CA – February 21, 2004
- “Management Strategies for PSA Recurrence after Radical Prostatectomy or Radiation Therapy”, University of California San Francisco (UCSF) Grand Rounds – April 14, 2004
- “Web-based Competency Evaluation System”, Society of University Urologists Annual Meeting, San Francisco, CA – May 7, 2004.
- “Current Controversies in Prostate Cancer”, Pellar Annual Endowed Lecture, Mayo Clinic, Scottsdale, AZ – June 7, 2004.
- “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium, San Francisco, CA – June 18, 2004.
- “Use of Adjuvant and Neoadjuvant Hormonal Therapy in Locally Advanced Prostate Cancer”, Asian Prostate Cancer Lecture Series: Bangkok, Thailand, Manilla, Philippines and Taipei, Taiwan – July 10-18, 2004.
- “What’s New and in the News: Early Stage Treatment for Prostate Cancer 2004” – Perspectives in Men’s Health Regional Program, San Francisco, CA – July 23, 2004.

- “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium, Washington, DC – July 30, 2004.
- “Update on Prostate Cancer Screening and Biopsy Techniques” and “Optimal Integration of Chemotherapy and Hormonal Therapy for Biochemical Recurrence”– ICPME Regional Symposium, Dearborn, MI – August 13, 2004.
- “Diagnosis and Treatment of Penile and Urethral Cancer” – Western Section AUA Meeting PREP-C Course, San Diego, CA – August 23, 2004.
- “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation Therapy” University of Minnesota Medical Center, Minneapolis, MN – September 22, 2004
- “Incorporating the ACGME Competencies Into a Residency Program: The Naval Medical Center San Diego Urology Experience” University of Minnesota Medical Center, Minneapolis, MN – September 22, 2004
- “Update on the Diagnosis and Treatment of Penile and Urethral Cancer” – University of Mississippi, Jackson, MS – November, 2004.
- “Optimal Integration of Chemotherapy and Hormonal Therapy for Biochemical Recurrence”– ICPME Regional Symposium, Los Angeles, CA – November 5, 2004.
- “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation Therapy” - Shands Hospital, University of Florida, Gainesville, FL – January 12, 2005.
- “Residency Education in Military Urology Training Programs – Incorporation of the ACGME Competencies and Duty Hour Restrictions” – Kimbrough Urologic Seminar, Honolulu, HI – January 17, 2005.
- “Who is Most Likely to Progress?” – Issues and Controversies in Prostate Care 2005, Jamaica, W.I. - March 11, 2005.
- “Obesity and Prostate Cancer” – 1st Annual DukeProstateCenter (DPC) Symposium: Carolina Prostate Cancer Clinical Trials and Care Update - 2005, Duke University Medical Center, Durham, NC – April 9, 2005.
- “New Concepts in Prostate Cancer Screening and Prevention”, Recent Advances in the Management of Prostate Cancer, Los Angeles, CA – April 22, 2005.
- “Evidence-Based Use of Neoadjuvant and Adjuvant Hormonal Therapy” - AUA Postgraduate Course, San Antonio, TX - May 23, 2005.
- “Obesity and Prostate Cancer” – UAB Comprehensive Cancer Center Retreat and Research Competition, Birmingham, AL – August 25, 2005.
- “Obesity and Prostate Cancer” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005.
- “Use of Neoadjuvant and Adjuvant Hormonal Therapy with Radical Prostatectomy and Radiotherapy” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005.
- “Management of PSA Recurrences After Radical Prostatectomy Case Presentations” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005.
- “Overview and Update on Penile and Urethral Cancer” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005.
- “Clinical Applications of PSA Kinetics” – Sixth Annual Society of Urologic Oncology Meeting, Bethesda, MD – December 2-3, 2005.
- “Point-Counterpoint: Are the Technological Advances in the Surgical Management of Prostate Cancer Truly Advances?” – 53rd Kimbrough Urologic Seminar, Savannah, GA – January 15-20, 2006.
- “Clinical Applications of PSA Kinetics in Prostate Cancer” – University of Kentucky, Lexington, KY – February 15, 2006.
- “PSA Kinetics” – TAP University, Las Vegas, NV – February 22, 2006.

- “Clinical Applications of PSA Kinetics” – University Associates of North Texas, Dallas, TX – April 11, 2006.
- “Obesity and Prostate Cancer” – Advances in Uro-Oncology: Eine Festschrift for Horst Zincke, MD, PhD, Rochester, MN – April 29, 2006.
- “Hormonal Therapy and Prostate Cancer: New Uses for an Old Treatment” – AUA Postgraduate Course, Atlanta, GA – May 24, 2006.
- “Treatments and Risk Factors for Prostate Cancer” – Conference on Cancer Survivorship Issues in the African-American Community, Birmingham, AL – June 6, 2006.
- “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care”, Tampa, FL – June 16, 2006.
- “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care”, Tampa, FL – June 16, 2006.
- “Clinical Applications of PSA Kinetics in Prostate Cancer” – Urology Seminar, Destin, FL – July 13-16, 2006.
- “Update on Robotic Prostatectomy for Prostate Cancer” – University of Alabama at Birmingham, Department of Surgery Grand Rounds, Birmingham, AL – August 17, 2006.
- “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care, Washington, DC – September 15, 2006.
- “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care, Washington, DC – September 15, 2006.
- “Robotics, Laparoscopic and Open Prostatectomy Options” – Annual Multidisciplinary Approach to the Management of Prostate and GU Cancer Conference, Dallas, TX – September 29-October, 1 2006.
- “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care”, Chicago, IL – October 27, 2006.
- “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care”, Chicago, IL – October 27, 2006.
- “Robotic Prostatectomy” – 4th Annual Georgia Urological Association Spring Meeting & Urology Resident Research Expo, Savannah, GA – February 16-18, 2007.
- “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2007.” – AUA Postgraduate Course, Anaheim, CA - May 2007.
- “Chemoprevention / Risk Factors for Prostate Cancer” – The Minnesota Urological Society Annual Spring Seminar, St Paul, MN – May 11-12, 2007.
- “New and Emerging Technologies in Prostate Cancer Prevention, Diagnosis and Treatment” – Prostate Cancer Summit 2007 Call to Action, Birmingham, AL – June 2007.
- “Point-Counterpoint: Is Robotic Prostatectomy Really Better than Open Prostatectomy?” – Urology Seminar, Destin, FL – August 9-12, 2007.
- “The Role of Radical Prostatectomy in High Risk Prostate Cancer” – Urology Seminar, Destin, FL – August 9-12, 2007.
- “Core Competencies” University of Alabama School of Medicine Surgery Grand Rounds, Birmingham, AL – August 23, 2007.
- “The Role of Obesity in Urology” – AUA Northeastern Section Meeting, Rochester, NY – September 6-7, 2007.
- “Current Challenges in Urology Residency Training” – AUA Northeastern Section Meeting, Rochester, NY – September 6-7, 2007.
- “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2008.” – AUA Postgraduate Course, Orlando, FL - May 2008.

RESEARCH SUPPORT

Current:

- **TNG-CL005, Tengion, Inc.** – A Multicenter Study to Obtain Full Thickness Bladder Tissue Specimens from Subjects Undergoing Cystectomy
Role: PI 1/1/2007-7/31/2009 \$25,494
Purpose: To obtain full-thickness bladder wall tissue at the time of cystectomy for use in development of bladder tissue constructs
- **UAHSF Endowment Grant** – UAB Men’s Contience Center
Role: CI 3/1/2008-2/28/2010 \$164,680
Purpose: To follow a cohort of men undergoing radical prostatectomy and collect follow-up data on health status and quality-of-life for one year after surgery
- **NCI N01-CN-75022** – Prostate, Lung, Colo-rectal and Ovarian (PLCO) Cancer Screening Trial
Role: CI 9/1/2007-9/29/2009 \$9,372
Purpose: Evaluate effectiveness of screening for prostate cancer; includes a biorepository (blood samples) and accompanying data collection on risk factors
- **VA01162 Cooperative Studies Program** – Chemotherapy after Prostatectomy for High Risk Prostate Cancer: A Phase III Randomized Study
Role: CI 1/1/2008-12/31/2008
Purpose: Investigate effectiveness of adjuvant chemotherapy to decrease recurrence rate after radical prostatectomy for high risk prostate cancer patients
- **2008 GSR-DG** - Geriatrics Education for Specialty Residents Dissemination Grant
Role: CI 7/1/2008-6/30/2009 \$25,000
Purpose: Improvement of geriatric education among urology residents by development and implementation of curricula and expansion of research focusing on the geriatric population
- **UAB X030820007** – Protocol for Obtaining Solid Tissues, Fluids, and Information for Genitourinary Cancer Research
Role: PI 1/1/2006-12/31/2009
Purpose: Develop tissue and body fluid repository for use in urologic cancer research

Pending:

- **UAB 0516 (NCI -University of Wisconsin Consortium)** – Phase II Study of Isoflavone G-2535 (Genistein) in Patients with Bladder Cancer
Role: CI
- **UAB 0810 (NCI -University of Wisconsin Consortium)** – Phase II Randomized Placebo-Controlled Trial of Polyphenono-E to Evaluate Bladder Tissue Levels of EGCG
Role: CI

PEER-REVIEWED PUBLICATIONS

1. Crain DS, Roberts JL, Amling CL: Practice patterns in vasectomy reversal surgery: A questionnaire study among practicing urologists. J Urol 171:311-5, 2004
2. Crain DS, Amling CL Kane CJ: Palliative TURP for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171:668-71, 2004.
3. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Onc 22:439-45, 2004
4. Altamar HO, Middleton GW, Capozza TA, Auge BK, Amling CL: Profound anemia from duodenal invasion of metastatic testicular seminoma. J Urol 171:344-5, 2004.

5. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK: Impact of obesity on biochemical control following radical prostatectomy for clinically localized prostate cancer. *J Clin Onc* 22:446-53, 2004.
6. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackman S, Moul JW: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. *J Clin Oncol* 21(21):4001-8, 2003.
7. Freedland SJ, Amling CL, Terris MK, Presti JC Jr, Aronson WJ, Elashoff D, and Kane CJ. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH Database. *Prostate Cancer Prostatic Dis*. 2003;6(3):261-265.
8. Moul J, Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Wu H. A retrospective review on 542 cases in the past decade on associations between bone metastasis and PSA level, bone pain, and race in prostate cancer patients. *Oncology* 17(4 Suppl):47-78, 2003
9. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC: The percentage of prostate needle biopsy cores with cancer from the more involved side of the biopsy as a predictor of PSA recurrence following radical prostatectomy. *Cancer* 98(11):2344-50, 2003.
10. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department of defense (DOD) Center for Prostate Disease Research (CPDR) national database. *Urol Oncol*. 2003; 21(6):447-55.
11. Freedland SJ, Presti JC Jr., Kane CJ, Aronson WJ, Terris MK, Dorey F, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? *Urology* 63:518-22, 2004.
12. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. *J Urol* 171:1141-1147, 2004
13. Wu H, Sun L, Moul JW, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. *J Urol* 171:1111-1116, 2004.
14. Sur RL, Borboroglu PG, Roberts JL, Amling, CL. A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity. *Prostate Cancer Prostatic Dis* (Epub ahead of print) 2004.
15. Freedland SJ, Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, Kane CJ. Predictors of PSA progression among men with seminal vesicle invasion at the time of radical prostatectomy. *Cancer* 100:1633-8, 2004.
16. Crum NF, Spencer CR, Amling CL: Prostate cancer among human immunodeficiency virus (HIV) –infected men. *Cancer* 101:294-9, 2004.
17. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL Presti JC, Dorey F, Aronson WJ: Pre-operative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. *J Urol* 171: 2215, 2004.
18. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, Amling CL. Biochemical outcome following radical prostatectomy among men with normal pre-operative serum PSA values. *Cancer* 101:748-53, 2004.
19. Crain DS, Spencer CR, Favata MA, Amling CL: Transureteral iced saline to obtain renal hypothermia: Potential for application in laparoscopic partial nephrectomy. *JSL* 8:217-222, 2004.

20. Freedland SJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, Trock B, and Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for pathologically organ-confined disease with negative surgical margins. *J Urol* 172:520-4, 2004.
21. Amling CL: Biochemical failure: role for early hormonal therapy. *BJU Int* 94 Suppl 3:9-10, 2004.
22. Amling CL: Advanced prostate cancer treatment guidelines: a United States perspective. *BJU Int* 94 Suppl 3:7-8, 2004
23. Amling CL: The association between obesity and the progression of prostate and renal cell carcinoma. *Urol Oncol* 22(6):478-84, 2004.
24. Amling, CL: Case studies in prostate cancer. *BJU Int* 94 Suppl 3:18-9, 2004.
25. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multi-institutional evaluation of depo-provera for the treatment of hot flashes associated with androgen ablation for prostate cancer. *J Urol* 174: 642-645, 2005.
26. Gaylis FD, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ: Prostate cancer in men using testosterone supplementation. *J Urol* 174: 534-538, 2005.
27. Amling CL: Relationship between obesity and prostate cancer. *Curr Opin Urol* 15(3): 167-171, 2005.
28. Langenstroer P, Kramer B, Cutting B, Amling C, Poulton T, Lance R, Thrasher JB: Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. *J Urol* 174: 642-645, 2005.
29. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR: A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: Diagnosis, pathogenesis, and management. *AIDS Patient Care STDS* 19: 655-71, 2005.
30. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ: Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. *J Clin Oncol*: 23: 7546-54, 2005.
31. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK; Shared Equal Access Regional Cancer Hospital Database Study Group: Radical differences in prognostic value of adult height for biochemical progression following radical prostatectomy. *Clin Cancer Res* 11: 7735-42, 2005.
32. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK: Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. *J Urol* 175: 500-4, 2006.
33. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK, SEARCH Database Study Group: Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. *J Urol* 175: 1298-302, 2006.
34. Amling CL: Biochemical recurrence after localized treatment. *Urol Clin North Am* 33: 147-59, 2006.
35. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ: Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. *Cancer* 107: 1265-72, 2006.
36. Amling CL: Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening? *Curr Treat Options Oncol* 7: 337-45, 2006.
37. Amling CL: Dilemmas in management of the small renal mass. *Curr Opin Urol* 16: 315-6, 2006.
38. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR: Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. *Cancer* 107: 2384-91, 2006.
39. Morey AF, Evans LA, McDonough RC, Park AM, Sexton WJ, Basler JW, Santucci RA, Amling CL, O'Reilly KJ: Evaluation of mechanical bowel preparation methods in urinary diversion surgery. *Can J Urol* 13: 3250-4, 2006.

40. Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ: Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? *J Urol* 176: 2453-8, 2006.
41. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Fredland SJ, SEARCH Database study group: Changing nature of high risk patients undergoing radical prostatectomy. *J Urol* 177: 113-7, 2007.
42. Crum-Cianflone NJ, Bavaron M, Hale B, Amling CL, Truett A, Brandt C, Pope B, Furtek K, Medina S, Wallace MR: Erectile dysfunction and hypogonadism among men with HIV. *AIDS Patient Care STDS* 21: 9-19, 2007.
43. Plante MK, Marks LS, Anderson R, Amling CL, Rukstalis D, Badlani G, Getlin L, Vang E: Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. *J Urol* 177: 1030-5, 2007.
44. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, SEARCH Database Study Group: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. *Urology* 69: 495-9, 2007.
45. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL, Hammontree LN, Kolettis PN: Computerized tomographic angiography for renal donor evaluation leads to a higher exclusion rate. *J Urol* 177: 1826-9, 2007.
46. King CR, Freedland SJ, Terri MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr: Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. *Urology* 69: 732-7, 2007.
47. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr: Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: A report from the SEARCH database. *Urology* 69: 921-6, 2007.
48. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Mangold LA, Freedland SJ: Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? *Urology* 69: 1138-42, 2007.
49. Sajadi KP, Terris MK, Hamilton RK, Cullen J, Amling CL, Kane CJ, Presti JC Jr, Aronson WJ, Freedland SJ: Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. *J Urol* 178: 990-5, 2007.
50. Scales CD Jr., Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, for the SEARCH Database Study Group: Predicting unilateral prostate cancer based on biopsy features: Implications for focal ablative therapy-Results from the SEARCH Database. *J Urol* 178: 1249-52, 2007.
51. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ; SEARCH Database Study Group: Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: Results from the SEARCH Database. *Urology* 70(2): 277-82, 2007.
52. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terri MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. *JAMA* 298 (19): 2275-80, 2007.
53. Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Fredland SJ: Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: Results from the SEARCH Database. *Cancer* 110(10): 2153-4, 2007.
54. Buschemeyer WJ 3rd, Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. *J Urol* 179: 124-9, 2008.
55. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. *Urology* 71(1):151-5, 2008.

56. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ; SEARCH Database Study Group: Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: Results from the SEARCH database. *J Urol* 179(2): 523-7, 2008.
57. Sengupta S, Amling C, D'Amico AV, Blute ML: Prostate specific antigen kinetics in the management of prostate cancer. *J Urol* 179(3):821-6, 2008.
58. Strang AM, Lockhart ME, Amling CL, Kolettis PN, Burns JR: Living renal donor allograft lithiasis: A review of stone related morbidity in donors and recipients. *J Urol* 179(3):832-6, 2008.
59. Colli JL, Amling CL: Exploring causes for declining prostate cancer mortality rates in the United States. *Urol Oncol*. 2008 Jan 11. [Epub ahead of print]
60. Colli JL, Amling CL: Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America. *Prostate Cancer Prostatic Dis*. 2008 Feb 12. [Epub ahead of print]
61. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. *J Urol*. 2008 179(2):523-7.
62. Colli JL, Amling CL: High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. *Urol Oncol*. 2008 Feb 1. [Epub ahead of print]
63. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. *J Urol*. 2008, 179(5 Suppl):S53-9.
64. Cox J, Amling CL: Current decision-making in prostate cancer therapy. *Curr Opin Urol*. 2008, 18(3):275-8.
65. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. *J Urol*. 2008;179(5):1785-9; discussion 1789-90. Epub 2008 Mar 17.
66. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ; SEARCH Database Study Group: Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. *J Urol*. 2008;179(5):1791-6; discussion 1796. Epub 2008 Mar 17.
67. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, Kane CJ: Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. *Prostate Cancer Prostatic Dis*. 2008 Jul 15. Epub ahead of print.
68. Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ: Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Cancer databases. *Brit J Urol Internat* 2008 Sept; 102(8):969-74, Epub 2008 August 7.
69. SEARCH Database Study Group, Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ: Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. *Brit J Urol Internat* 2008 Sep; 102(8):964-8. Epub 2008 July 7.
70. Colli JL, Busby JE, Amling CL: Renal cell carcinoma rates compared with health status and behavior in the United States. *Urology* 2009 Feb; 73(2):431-6. Epub 2008 August 13.
71. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ; SEARCH Database Study Group. The association between prostate size and Gleason score upgrading

- depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. *Brit J Urol Internat* 2008 Nov; 102(9):1074-9. Epub 2008 Sep 3.
72. Teeter AE, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ, SEARCH Database Group: What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. *J Urol* 2008 Nov; 180(5):1980-4; discussion 1985. Epub 2008 Sep 17.
 73. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA: Structural heterogeneity and protein composition of exosome-like vesicles (prostatosomes) in human serum. *Prostate*. 2009 Feb 1; 69(2):159-67.
 74. Schroeck FR, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? *Brit J Urol Internat* 2009 Mar; 103(5):603-8. Epub 2008 Nov 18.
 75. Shah SE, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris MK: Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. *Brit J Urol Internat* 2009 Mar 4. Epub ahead of print.

INVITED PUBLICATIONS AND BOOK CHAPTERS

1. Amling CL: How the addition of hormones improves outcome: Hormone therapy and surgery. *Eur Urol Supplements* 3(1):27-31, 2004.
2. Amling CL: Letter of Response – Reaction to Body Mass Index, *Family Urology*, Vol 9, Issue 2, Summer 2004.
3. Amling CL: Commentary on Does Obesity Affect Outcome in Prostate Cancer. *Am J Urol Rev* 2(7):323-325, 2004
4. Amling CL. Hormonal therapy: orchiectomy. In: Bostwick D, Crawford D, Higano C, Roach M, eds. *Prostate Cancer Book*. American Cancer Society; Fall 2004 (In press)
5. Amling CL. Surgery: questions to ask your medical team about surgery. In: Bostwick D, Crawford D, Higano C, Roach M, eds. *Prostate Cancer Book*. American Cancer Society; Fall 2004 (In press)
6. Amling CL. Definition of failure recurrence after primary therapy – radical prostatectomy. In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. *Comprehensive Textbook of Genitourinary Oncology, 3rd Edition*. Philadelphia, PA; Lippincott, Williams & Wilkins (In press)
7. Amling CL. Relationship Between Obesity and Prostate and Renal Cancer – *Journal of Alternative and Complementary Medicine* (In press)
8. Amling CL. Evidence-Based Use of Neoadjuvant and Adjuvant Hormonal Therapy with Radiotherapy and Radical Prostatectomy. *AUA Postgraduate Course Handout*, May 2005.
9. Amling CL. Biochemical Recurrence after Localized Treatment, *Urologic Clinics of North America*, Vol 33, No 2, 2006.
10. Amling CL. Prostate-specific Antigen and Detection of Prostate Cancer: What Have We Learned about What Should We Recommend for Screening? In: *Current Treatment Options in Oncology*, 7:337-345, Philadelphia (PA), Current Science, 2006.
11. Amling CL and Clayton DB. Urologic Principles for the General Surgeon. In: *General Surgery: Principles and International Practice*, Northport (NY), Springer (In press).
12. Amling CL, section editor. Prostate Cancer. In: *Current Prostate Reports*, Vol 6, No 1, Philadelphia (PA): Current Medicine, February 2008.

PUBLISHED ABSTRACTS

1. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. *J Urol* 171 (supplement) 115, 2004.
2. Amling CL, Spencer CR, Roberts JL: Practice patterns in transrectal ultrasound guided prostate biopsy: Results of a questionnaire survey of practicing urologists. *J Urol* 171 (supplement) 478, 2004.
3. Wu H, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O'Reilly KJ, Hernandez J, Chung A, Smith K. Prostate cancer mortality after radical prostatectomy or radiation therapy in men with clinically localized prostate cancer. *J Urol* 171 (supplement) 118, 2004.
4. Chen Y, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O'Reilly KJ, Hernandez J, Chung A, Smith K. Contemporary experience with hormone refractory prostate cancer (HRPC-Stage D3) in the PSA era: Report from the DOD CPDR national database. *J Urol* 171 (supplement) 118, 2004.
5. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? *J Urol* 171 (supplement) 272, 2004.
6. Chung A, Sun L, Carter CA, Moul JW, Zhao X, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O'Reilly KJ, Hernandez J, Smith K. Changing face of prostate cancer in the PSA era: Results from the CPDR national database. *J Urol* 171 (supplement) 125, 2004.
7. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. *J Urol* 171 (supplement) 116, 2004.
8. Sexton WJ, McDonough RC, Hernandez J, Sun L, Moul JW, Amling CL, Donahue TF, Kusuda L, O'Reilly KJ, Chung A, Smith K. Prostate cancer in men less than or equal to 40 years of age during the PSA era. *J Urol* 171 (supplement) 126, 2004.
9. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr., Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. *J Urol* 171 (supplement) 332, 2004.
10. Amling CL, Williams SR, Lance R, McLeod DG, Kusuda L, Donahue T, Foley J, Sexton W, Soderdahl DW, Sun L, Moul JW: Does obesity increase intraoperative and postoperative complications in men undergoing radical prostatectomy? *J Urol* 171 (supplement) 215, 2004.
11. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer from the most involved side of the biopsy is a better predictor of PSA recurrence following radical prostatectomy than the total percent of cores with cancer. *J Urol* 171 (supplement) 274, 2004.
12. Amling CL, Sun L, Moul JW, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ, O'Reilly KJ, Hernandez J, Chung A, Smith K. Pre and post-surgery factors affecting the outcomes of patients with intermediate risk prostate cancer. *J Urol* 171 (supplement) 277, 2004.
13. Moul JW, Sun L, Amling CL, Fia Y, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ, O'Reilly KJ, Hernandez J, Chung A, Smith K. How long can radical prostatectomy (RP) safely be delayed? CPDR experience from 3324 cases. *J Urol* 171 (supplement) 312, 2004.
14. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multi-institutional evaluation of depo-provera for the treatment of hot flashes associated with androgen ablation for prostate cancer. *J Urol* 171 (supplement) 384, 2004.

15. Altamar HO, Kolkow, S, Amling CL: Incidental genitourinary abnormalities detected by CT colonography in a large colorectal cancer screening population. *J Urol* 173 (supplement) 384, 2005.
16. Sarvis J, Crain D, Williams S, Amling CL: Randomized prospective comparison of IV conscious sedation and lidocaine block for prostate biopsy. *J Urol* 173 (supplement) 384, 2005.
17. Freedland SJ, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr., and Kane CJ. Prostate size and risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. *J Urol* 173 (supplement) 384, 2005.
18. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, and Terris MK: Agent Orange exposure and Risk of Advanced Disease and Biochemical Progression after Radical Prostatectomy: Results from the SEARCH Database. *J Urol* 175 (supplement) 42, 2006.
19. Bastian PJ, Gonzalgo ML, Mangold LA, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr., Epstein JI, Partin AW, and Freedland SJ: Pathological and Biochemical Outcomes after Radical Prostatectomy for Men with a Biopsy Gleason Score of 8 to 10. *J Urol* 175 (supplement) 215, 2006.
20. Scales CD Jr., Amling CL, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Freedland SJ: Can Unilateral Prostate Cancer be Reliability Predicted based upon Biopsy Features? *J Urol* 175 (supplement) 373, 2006.
21. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, and Terris MK: Obesity, Serum PSA, and Prostate Size: Implications for Prostate Cancer. *J Urol* 175 (supplement) 487, 2006.
22. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, and Carroll PR: Multi-institutional validation of the UCSF Cancer of the Prostate Risk Assessment (CAPRA) for prediction of recurrence following radical prostatectomy. *J Urol* 175 (supplement) 531, 2006.
23. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, and Presti JC Jr.: Upgrading and Downgrading of Prostate Needle Biopsies: Risk Factors and Clinical Implications. *J Urol* 175 (supplement) 534, 2006.
24. Nelles JL, Freedland SJ, Presti JC Jr., Terris MK, Aronson WJ, Amling CL, and Kane CJ: Nerve Sparing Does Not Increase the Risk of Biochemical Recurrence Results From the SEARCH Database. *J Urol* 177 (supplement) 6, 2007.
25. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr., Amling CL, and Freedland SL: Are the Partin Tables Accurate for African-American Men in the United States? *J Urol* 177 (supplement) 111, 2007.
26. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr.: The Optimal Timing, Cutoff and Method of Calculation of Preoperative PSA Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH. *J Urol* 177 (supplement) 128, 2007.
27. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr., and Freedland SJ: African American Race, Risk of Biochemical Recurrence, and PSADT after Radical Prostatectomy. *J Urol* 177 (supplement) 131, 2007.
28. Shah SR, Freedland SJ, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and Terris MK: Agent Orange Exposure Among Black Men is a Stronger Predictor of PSA Recurrence and Rapid Post-recurrence PSADT Than Among White Men. *J Urol* 177 (supplement) 153, 2007.
29. Freedland SJ, Hamilton RJ, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, and Kane CJ: Obesity, Risk of Biochemical Recurrence, and PSADT After Radical Prostatectomy. *J Urol* 177 (supplement) 154, 2007.
30. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, and Freedland SJ: Significance of the Apical Margin in Radical Prostatectomy: Results from the SEARCH Database. *J Urol* 177 (supplement) 159, 2007.

31. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr., and Freedland SJ: Is a Positive Bladder Neck Margin Truly a T4 Lesion in the PSA Era? *J Urol* 177 (supplement) 282, 2007.
32. Clayton DB, Colli JL, Seale JR, Stewart AF, Lin HY, and Amling CL: The Kinetics of Prostate Specific Antigen Decline as a Predictor of Outcomes in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. *J Urol* 177 (supplement) 337, 2007.
33. Banez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr., and Freedland SJ: Can Hemodilution Explain the Lower PSA Concentrations Among Obese Men? *J Urol* 177 (supplement) 468, 2007.
34. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL, Hammontree LN and Kolettis PN: Computed Tomographic Angiography for Renal Donor Evaluation Leads to Higher Exclusion Rate. *J Urol* 177 (supplement) 565, 2007.
35. Strang AM, Lockhart ME, Burns JR, Amling CL, and Kolettis PN: Short Term Outcomes of Living Donor Allograft Nephrolithiasis in Renal Transplant Donors and Recipients. *J Urol* 177 (supplement) 594, 2007.
36. Scales CD, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Krupski TL, and Freedland SJ: Does Practice Reflect the Evidence? Lymph Node Dissection with Radical Prostatectomy: Results from the SEARCH Database. *J Urol* 179 (supplement) 3, 2008.
37. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: Small TRUS Volume Predicts Clinically Significant Gleason Score Upgrading After Radical Prostatectomy: Results from the SEARCH Database. *J Urol* 179 (supplement) 51, 2008.
38. Teeter AE, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ: Does Early PSADT, Calculated Starting at the First Detectable PSA After Radical Prostatectomy (RP), Correlate with Standard PSADT? A Report from the SEARC Database Group. *J Urol* 179 (supplement) 65, 2008.
39. Banez LL, Hamilton RJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and Freedland SJ: Higher Cholesterol Increases the Risk of Biochemical Failure After Radical Prostatectomy: Results from the SEARCH Database Group. *J Urol* 179 (supplement) 68, 2008.
40. Teeter AE, Banez LL, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ: What Are the Factors Associated with a Short PSA Doubling Time? A Report from the SEARCH Database Group. *J Urol* 179 (supplement) 149, 2008.
41. Lin DW, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, and Freedland SJ: Outcome Among Men with Pathological Gleason SUM 8-10 Prostate Cancer at the Time of Radical Prostatectomy: Results from the SEARCH Database. *J Urol* 179 (supplement) 151, 2008.
42. Jayachandran J, Banez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, and Freedland SJ: Risk Stratification Among Men with Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. *J Urol* 179 (supplement) 251, 2008.
43. Kane CJ, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: PSA Velocity (PSAV) to Cancer-Specific PSA (PSA(PCA)) Ratio Increases with Higher Gleason Score: Results from the SEARCH Database. *J Urol* 179 (supplement) 601, 2008.
44. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Sun L, Moul JW, and Freedland SJ: Obesity as a Predictor of Adverse Outcome Across Black and White Race: Results from the SEARCH and Duke Prostate Center Databases. *J Urol* 179 (supplement) 647, 2008.
45. Kane CJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: Outcomes After Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results from the SEARCH Database. *J Urol* 179 (supplement) 651, 2008.

46. Klink JC, Banez LL, Powell IJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ: T1C Disease in Black Men: A More Aggressive Disease? Results from the SEARCH Database. *J Urol* 179 (supplement) 652, 2008.
47. Freedland SJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Kane CJ: Over the Last 15+ Years, the Percentage of Men Undergoing Radical Prostatectomy Who Are Candidates for Active Surveillance Has Not Changed: Results From the SEARCH Database. *J Urol* 179 (supplement) 653, 2008.
48. Colli JL, Stands C, Martin B, and Amling CL: Urologist Population Density and PSA Screening Practices Predict Prostate Cancer Mortality Rates in the United States. *J Urol* 179 (supplement) 687, 2008.
49. Freedland SJ, Moul JW, Sun L, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti JC, Amling CL, and Kane CJ: Dynamic Screening Detects Prostate Cancer (PC) Earlier and Would Lead to Improved Cancer Control: Results from the Duke Prostate Center and the SEARCH Database. *J Urol* 179 (supplement) 688, 2008.
50. Clayton DB, Spencer CL, and Amling CL: Practice Patterns of Transrectal Ultrasound Guided Prostate Biopsy: Results of a Questionnaire Survey of Practicing Urologists. *J Urol* 179 (supplement) 712, 2008.
51. Banez LL, Sun L, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Moul JW, and Freedland SJ: Is PSA a Poor Predictor of Adverse Pathology and Biochemical Failure Following Radical Prostatectomy in Obese Men? *J Urol* 179 (supplement) 722, 2008.